Company Overview and News

Esprit to shut all Aussie stores

FASHION retailer Esprit will close all 67 of its loss-making Australia and New Zealand stores as the Hong Kong-listed company shifts focus to more profitable regions.

Esprit to close loss-making operations in Australia, New Zealand

2018-05-03 channelnewsasia
HONG KONG: Fashion group Esprit Holdings said on Thursday it plans to shut its loss-making operations in Australia and New Zealand, concentrating resources in developing Asian markets in China, Hong Kong, Taiwan, Singapore and Malaysia.

What's In Store For Oxford Industries?

2018-04-02 seekingalpha
The firm will grow organically through on boarding new employees and increasing their online presence. Further organic growth will be realized through the opening of new stores.

Struggling Esprit to close more than 40 shops in Europe

2018-02-28 scmp
Retailer is hammered by net loss of US$121.9 million for second half of last year, compared with a net profit of US$7.79 million for the same period in 2016

Esprit warns of US$125m loss as China business takes a hit

2018-01-25 scmp
Once the darling of retail analysts, the stock has lost 97pc since prices peaked in 2007

C-Mer’s Lam is Hong Kong’s richest ophthalmologist, after shares soar fourfold in IPO week

2018-01-21 scmp
Dr Dennis Lam Shun-chiu, the popular ophthalmologist who founded C-Mer Eye Care Holdings, has become Hong Kong’s richest eye doctor – and perhaps one of the world’s richest medical professionals.

Former Esprit chairman transfers US$115m in shares to his two daughters

2017-10-12 scmp
Claudine Lauren Ying, 29, and the younger Eileen Ying, 20, now own half each of a new company Total Market, into which the shares have been transferred

Esprit Holdings Ltd. ADR 2017 Q4 - Results - Earnings Call Slides

2017-09-21 seekingalpha
The following slide deck was published by Esprit Holdings Ltd. ADR in conjunction with their 2017 Q4 earnings call.

Retail sector dominates buybacks and shareholder dealings

2017-08-13 scmp
While buying plunged, buyback activity rose for the first time in five weeks with 10 firms posting 60 repurchases worth HK$588 million

Lands' End Chief Executive Officer Jerome Griffith Joins Company Today Bringing Extensive Experience From Iconic Consumer Brands

2017-03-07 prnewswire
DODGEVILLE, Wis., March 6, 2017 /PRNewswire/ -- Today, Jerome Griffith started in his role as the Chief Executive Officer of Lands' End, Inc.  Mr. Griffith brings a wide range of consumer brand experience to the company, most recently serving as President and Chief Executive Officer at Tumi Holdings, Inc. He has also joined the Lands' End Board of Directors.

Esprit may raise prices in Europe to offset weakening euro, says CEO

2017-02-22 scmp
One of the world’s top apparel brands said it may consider raising prices in Europe if the euro depreciates sharply as pressure continues to pile up for retailers in a region where shifting exchange rates have already eaten into revenues.

Hong Kong stocks rise after Dow extends rally to 8th day

2017-02-22 scmp
Hysan Development, New World Development, Sino Land, Anta, Esprit, Bossini due to unveil financial results on Wednesday

Fashion’s Jürgen Friedrich Relists Plaza Hotel Condo, This Time for $39.5 Million - WSJ

2017-02-14 wsj
Jürgen Friedrich is trying again to sell his Plaza spread, this time listing it for $39.5 million, or 28% less than its asking price in 2008.

Lands' End again taps high end retail world for new CEO

2016-12-20 fortune
Only a few months after firing a CEO with deep roots in the world of luxury, Lands’ End le has again tapped an executive with experience in upscale retail to lead it out of a protracted slump.

Solving Climate Change With Beer From Patagonia’s Food Startup - Bloomberg

2016-10-03 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

13h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

13h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...